Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.

Alex K BryantAnthony V D'AmicoPaul L NguyenJohn P EinckChristopher J KaneRana R McKayDaniel R SimpsonArno J MundtJames D MurphyBrent S Rose

Published in: Cancer (2018)

The 3-month post-RT PSA level appears to be a strong prognostic biomarker for bPFS, PCSS, and OS in patients with intermediate-risk and high-risk prostate cancer, particularly those with high-risk disease. The 3-month PSA measurement may augment clinical decision making and holds promise as a potential surrogate endpoint in clinical trials. Cancer 2018;124:2939-47. © 2018 American Cancer Society.

Keyphrases

prostate cancer
radical prostatectomy
papillary thyroid
clinical trial
decision making
squamous cell
early stage
radiation therapy
squamous cell carcinoma
radiation induced
randomized controlled trial
risk assessment
big data
mesenchymal stem cells
open label
climate change
phase ii
cell therapy
double blind